57歲李姓男子為Ｂ型肝炎帶原者，平時沒有定期接受追蹤檢查，在一次健康檢查中赫然發現肝臟有顆11公分的肝癌，且已轉移到肝臟左葉，經影像及血管檢查確診為肝癌中期，依照以往臨床案例統計，肝癌中期的平均存活期為10多個月，5年存活率僅約2成。幸好他的兒子捐肝救父，手術十分成功，李先生與家人也能續享天倫之樂。
成大醫院移植外科主任林毅志醫師說明，考量腫瘤分布與肝功能情形，患者已排除手術切除，在建議下病人最後接受經肝動脈化學栓塞術，並成功縮小腫瘤，達到可進行肝臟移植的標準，而即將步入婚姻的兒子，也願意捐贈肝臟，為父親的生命與健康盡一份心力。
laennec林毅志醫師說，肝臟已有病理變化的病人，醫師必須同時考量腫瘤、肝機能及病患整體健康狀態，能接受積極手術切除的並不多，再加上病人接受治療後，已有慢性肝炎或肝硬化之剩餘肝臟，仍是發生肝癌的危險環境。
治療肝癌的策略雖然很多，但是復發機率仍然很高，手術切除後的病人5年復發率高達5至7成，更遑論接受其他治療成效較差的病患。
以李先生的案例，雖然剛診斷時的期別已超出標準，但經過栓塞等降階治療可以達到標準，其接受肝移植的存活率與原來就符合換肝標準不必降階治療的病人相當，5年復發率可以降到約1成。
林毅志指出，積極治療是保命的重要關鍵，每位病人的病況不同，並非治療後都能成功降期，但及早發現即時治療，就有望延長生命。
The 57-year-old man surnamed Li was originally admitted to the hepatitis B. He was not regularly followed up. In a health check, he found a liver of 11 cm in the liver and had metastasized to the left lobe of the liver. The diagnosis was confirmed by imaging and vascular examination. In the middle stage of liver cancer, according to the statistics of previous clinical cases, the average survival time of liver cancer in the middle stage is more than 10 months, and the 5-year survival rate is only about 20%. Fortunately, his son donated his liver to save the father. The operation was very successful. Mr. Li and his family can continue to enjoy the family.
Dr. Lin Yizhi, director of the Department of Transplantation Surgery, Chengda Hospital, explained that the patient's distribution and liver function were considered. The patient had been excluded from the surgical resection. The patient was finally recommended to undergo transcatheter arterial chemoembolization and successfully reduced the tumor to meet the standard for liver transplantation. The son who is about to enter the marriage is willing to donate the liver to do his part for his father's life and health.
Dr. Lin Yizhi said that patients with pathological changes in the liver must consider the tumor, liver function and overall health of the patient. There are not many active surgical resections. In addition, patients have chronic hepatitis after receiving treatment. Or the remaining liver of cirrhosis, is still a dangerous environment for liver cancer.
Although there are many strategies for treating liver cancer, the chance of recurrence is still high. The 5-year recurrence rate of patients after surgical resection is as high as 5 to 70%, let alone patients with poor treatment results.
In the case of Mr. Li, although the period at the time of diagnosis has exceeded the standard, the standard of reduction after embolization can reach the standard, and the survival rate of the liver transplant is equivalent to that of the patient who has not met the reduced liver standard. The 5-year recurrence rate can be reduced to about 10%.
Lin Yizhi pointed out that active treatment is an important key to life-saving. Each patient's condition is different. It is not a successful period after treatment. However, early detection of immediate treatment is expected to prolong life.
Laennec is the ethical drug manufactured with JBP’s unique technologies.
Laennec is the ethical drug manufactured with JBP’s unique technologies for effective extraction of variety of growth factors, cytokines, and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver. Our product safety is ensured by the most rigid safety measures among existing scientific standards.
留言列表
